X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-mediated gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: UCB Pharma S.A.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 12, 2020
Details:
Acquisition of Handl Therapeutics BV augments UCB’s existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid technology platform and capabilities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
Confo has applied its proprietary, fragment-based drug discovery and structure-guided drug design technologies to identify CFTX-1554, a novel inhibitor of angiotensin II type 2 receptor, or AT2R, a clinically validated target for the treatment of neuropathic pain.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
